Assessment of Clinical Outcomes in Patients With Osteoarthritis: Analysis From the UK Medical Cannabis Registry

References

• Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage. 2015;23(8):1233–41. doi:10.1016/j.joca.2015.03.036.
   PubMed Web of Science ®Google Scholar
• Caporali R, Cavagna L, Montecucco C. Pain in arthritis. Eur J Pain Supp. 2012;3(S2):123–7. doi:10.1016/j.eujps.2009.07.009.
   Google Scholar
• Priority medicines for Europe and the world. (Recent publications, information and events). WHO Drug Information. 2005;19(4):308. https://search.proquest.com/docview/215678671.
   Google Scholar
• Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–96. doi:10.1016/S0140-6736(12)61729-2.
   Google Scholar
• Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–223.
   PubMed Web of Science ®Google Scholar
• March L, Smith EUR, Hoy DG, Cross MJ, Sanchez-Riera L, Blyth F, Buchbinder R, Vos T, Woolf AD. Burden of disability due to musculoskeletal (MSK) disorders. Best Pract Res Clin Rheumatol. 2014;28(3):353–66. doi:10.1016/j.berh.2014.08.002.
   PubMed Web of Science ®Google Scholar
• James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858. doi:10.1016/S0140-6736(18)32279-7.
   PubMed Web of Science ®Google Scholar
• Pitcher MH, Von Korff M, Bushnell MC, Porter L. Prevalence and profile of high-impact chronic pain in the United States. J Pain. 2019;20(2):146–60. doi:10.1016/j.jpain.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Fitzcharles M-A, Shir Y. New concepts in rheumatic pain. Rheum Dis Clin North Am. 2008;34(2):267–83. doi:10.1016/j.rdc.2008.03.005.
   PubMed Web of Science ®Google Scholar
• Schofield D, Cunich M, Shrestha RN, Tanton R, Veerman L, Kelly S, Passey ME. The long-term economic impacts of arthritis through lost productive life years: results from an Australian microsimulation model. BMC Public Health. 2018;18(1):654. Doi:1186/s12889-018-5509-3.
   PubMedGoogle Scholar
• Osteoarthritis in over 16s: diagnosis and management. London (UK): National Institute for Health and Clinical Excellence (NICE); 2022.
   Google Scholar
• Ippolito M, Spurio G, Compagno V, Rizzo A, Di Simone M, Corsale AM, Mazzola G, Giarratano A, Meraviglia S, Cortegiani A, et al. Autologous conditioned serum for chronic pain in patients with osteoarthritis: a feasibility observational study. Br J Pain. 2023;17(1):103–11. doi:10.1177/20494637221134169.
   PubMed Web of Science ®Google Scholar
• van Laar M, Pergolizzi JV, Mellinghoff H-U, Merchante IM, Nalamachu S, O’Brien J, Perrot S, Raffa RB. Pain treatment in arthritis-related pain: beyond NSAIDs. Open Rheumatol J. 2012;6(1):320–30. doi:10.2174/1874312901206010320.
   PubMedGoogle Scholar
• Davis A, Robson J. The dangers of NSAIDs: look both ways. Br J Gen Pract. 2016;66(645):172–3. doi:10.3399/bjgp16X684433.
   PubMed Web of Science ®Google Scholar
• Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Phys. 2008;2s;11(3;2s):S105–S20. doi:10.36076/ppj.2008/11/S105.
   Google Scholar
• Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA. 2021;325(6):568–78. doi:10.1001/jama.2020.22171.
   PubMed Web of Science ®Google Scholar
• Divekar A, Divekar O, M Navaratnam D, Shrivastava R. Impact of the harm review service for patients awaiting elective hip and knee surgeries for more than 52 weeks. Curēus. 2022;14(4):e23805. doi:10.7759/cureus.23805.
   PubMed Web of Science ®Google Scholar
• McCracken LM. Personalized pain management: is it time for process-based therapy for particular people with chronic pain? Eur J Pain. 2023;27(9):1044–55. doi:10.1002/ejp.2091.
   PubMed Web of Science ®Google Scholar
• Mobasheri A, Batt M. An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med. 2016;59(5-6):333–9. doi:10.1016/j.rehab.2016.07.004.
   PubMed Web of Science ®Google Scholar
• La Porta C, Bura SA, Negrete R, Maldonado R. Involvement of the endocannabinoid system in osteoarthritis pain. Eur J Neurosci. 2014;39(3):485–500. doi:10.1111/ejn.12468.
   PubMed Web of Science ®Google Scholar
• Costa B, Comelli F. Handbook of cannabis. Oxford (UK): Oxford University Press; 2014.
   Google Scholar
• Maldonado R, Baños JE, Cabañero D. The endocannabinoid system and neuropathic pain. Pain (Amsterdam). 2016;157 Suppl 1(Supplement 1):S23–S32. doi:10.1097/j.pain.0000000000000428.
   Google Scholar
• Compton DR, Dewey WL, Martin BR. Cannabis dependence and tolerance production. Adv Alcohol Subst Abuse. 1990;9(1-2):129–47. https://search.proquest.com/docview/232157757. doi:10.1300/J251v09n01_08.
   PubMedGoogle Scholar
• Rodríguez MJ, Robledo P, Andrade C, Mahy N. In vivo co‐ordinated interactions between inhibitory systems to control glutamate‐mediated hippocampal excitability. J Neurochem. 2005;95(3):651–61. doi:10.1111/j.1471-4159.2005.03394.x.
   PubMed Web of Science ®Google Scholar
• Ishac EJN, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol. 1996;118(8):2023–8. doi:10.1111/j.1476-5381.1996.tb15639.x.
   PubMed Web of Science ®Google Scholar
• Mbvundula EC, Bunning RAD, Rainsford KD. Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1alpha-induced matrix degradation in bovine articular chondrocytes in-vitro. J Pharm Pharmacol. 2006;58(3):351–8. https://www.ncbi.nlm.nih.gov/pubmed/16536902. doi:10.1211/jpp.58.3.0009.
   PubMed Web of Science ®Google Scholar
• Whyte L, Ford L, Ridge S, Cameron G, Rogers M, Ross R. Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. Br J Pharmacol. 2012;165(8):2584–97. doi:10.1111/j.1476-5381.2011.01519.x.
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature (London). 1993;365(6441):61–5. doi:10.1038/365061a0.
   PubMed Web of Science ®Google Scholar
• Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232(1):54–61. doi:10.1111/j.1432-1033.1995.tb20780.x.
   PubMedGoogle Scholar
• Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 2006;103(3):696–701. doi:10.1073/pnas.0504187103.
   PubMed Web of Science ®Google Scholar
• Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M, Guijarro A, Lodola A, Armirotti A, Garau G, et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci. 2011;15(1):64–9. https://escholarship.org/uc/item/3913r252
   PubMed Web of Science ®Google Scholar
• Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D, Cuomo V. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int Rev Neurobiol. 2009;85:57–72. doi:10.1016/S0074-7742(09)85005-8.
   PubMed Web of Science ®Google Scholar
• La Porta C, Bura SA, Llorente-Onaindia J, Pastor A, Navarrete F, García-Gutiérrez MS, De la Torre R, Manzanares J, Monfort J, Maldonado R, et al. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain (Amsterdam). 2015;156(10):2001–12. doi:10.1097/j.pain.0000000000000260.
   Google Scholar
• Kwong FNK, Richardson SM, Evans CH. Chordin knockdown enhances the osteogenic differentiation of human mesenchymal stem cells. Arthritis Res Ther. 2008;10(3):R65. doi:10.1186/ar2436.
   PubMed Web of Science ®Google Scholar
• Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, Kendall DA, Scammell BE, Reeve AJ, Chapman V, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R43. doi:10.1186/ar2401.
   PubMed Web of Science ®Google Scholar
• Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1-2):1–25. doi:10.1016/j.jep.2006.02.001.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin. Br J Pharmacol. 2007;153(2):199–215. doi:10.1038/sj.bjp.0707442.
   PubMed Web of Science ®Google Scholar
• Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62(4):588–631.
   PubMed Web of Science ®Google Scholar
• Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L, Sweeney JM, Miyauchi JT, Tsirka SE, Ojima I, et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem. 2015;290(14):8711–21. doi:10.1074/jbc.M114.618447.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(3):e94. doi:10.1038/tp.2012.15.
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Bagher AM, Kelly MEM, Denovan‐Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790–805. doi:10.1111/bph.13250.
   PubMed Web of Science ®Google Scholar
• Nadal X, La Porta C, Andreea Bura S, Maldonado R. Involvement of the opioid and cannabinoid systems in pain control: new insights from knockout studies. Eur J Pharmacol. 2013;716(1-3):142–57. doi:10.1016/j.ejphar.2013.01.077.
   PubMed Web of Science ®Google Scholar
• Simão da Silva KAB, Paszcuk AF, Passos GF, Silva ES, Bento AF, Meotti FC, Calixto JB. Activation of cannabinoid receptors by the pentacyclic triterpene α,β-amyrin inhibits inflammatory and neuropathic persistent pain in mice. Pain (Amsterdam). 2011;152(8):1872–87. Doi: pain.2011.04.005. doi:10.1016/j.pain.2011.04.005.
   Google Scholar
• Casey SL, Atwal N, Vaughan CW. Cannabis constituent synergy in a mouse neuropathic pain model. Pain (Amsterdam). 2017;158(12):2452–60. doi:10.1097/j.pain.0000000000001051.
   Google Scholar
• Schuelert N, McDougall JJ. Cannabinoid‐mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis Rheum. 2008;58(1):145–53. doi:10.1002/art.23156.
   PubMedGoogle Scholar
• Philpott HT, O’Brien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017;158(12):2442–51. doi:10.1097/j.pain.0000000000001052.
   PubMed Web of Science ®Google Scholar
• Wang L, Hong PJ, May C, Rehman Y, Oparin Y, Hong CJ, Hong BY, AminiLari M, Gallo L, Kaushal A, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021;374:n1034. doi:10.1136/bmj.n1034.
   PubMed Web of Science ®Google Scholar
• Bapir L, Erridge S, Nicholas M, Pillai M, Dalavaye N, Holvey C, Coomber R, Hoare J, Khan S, Weatherall MW, et al. Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: a cohort study. Expert Rev Neurother. 2023;23(3):281–95. doi:10.1080/14737175.2023.2181696.
   PubMed Web of Science ®Google Scholar
• Frane N, Stapleton E, Iturriaga C, Ganz M, Rasquinha V, Duarte R. Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study. J Cannabis Res. 2022;4(1):47. doi:10.1186/s42238-022-00154-9.
   PubMedGoogle Scholar
• Schubert EA, Johnstone MT, Benson MJ, Alffenaar JC, Wheate NJ. Medicinal cannabis for Australian patients with chronic refractory pain including arthritis. Br J Pain. 2023;17(2):206–17. doi:10.1177/20494637221147115.
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare Products Regulatory Agency. The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use in humans. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/869284/Cannabis_Guidance__unlicensed_CBPMs__updated_2020.pdf.
   Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9. jclinepi.2007.11.008. doi:10.1016/j.jclinepi.2007.11.008.
   PubMed Web of Science ®Google Scholar
• Brusselaers N, Lagergren J. The Charlson Comorbidity Index in Registry-based research. Methods Inf Med. 2017;56(5):401–6. doi:10.3414/ME17-01-0051.
   PubMed Web of Science ®Google Scholar
• Erridge S, Salazar O, Kawka M, Holvey C, Coomber R, Usmani A, Sajad M, Beri S, Hoare J, Khan S, et al. An initial analysis of the UK Medical Cannabis Registry: outcomes analysis of first 129 patients. Neuropsychopharmacol Rep. 2021;41(3):362–70. doi:10.1002/npr2.12183.
   PubMed Web of Science ®Google Scholar
• Lee D, de Keizer N, Lau F, Cornet R. Literature review of SNOMED CT use. J Am Med Inform Assoc. 2014;21(E1):E11–E19. doi:10.1136/amiajnl-2013-001636.
   PubMed Web of Science ®Google Scholar
• British National Formulary. Medicines guidance: prescribing in palliative care [cited 2023 Apr 15]. Available from: https://bnf.nice.org.uk/medicines-guidance/prescribing-in-palliative-care/.
   Google Scholar
• Kapstad H, Rokne B, Stavem K. Psychometric properties of the Brief Pain Inventory among patients with osteoarthritis undergoing total hip replacement surgery. Health Qual Life Outcomes. 2010;8(1):148. doi:10.1186/1477-7525-8-148.
   PubMedGoogle Scholar
• Jumbo SU, MacDermid JC, Kalu ME, Packham TL, Athwal GS, Faber KJ. Measurement properties of the Brief Pain Inventory-Short Form (BPI-SF) and Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) in pain-related musculoskeletal conditions: a systematic review. Clin J Pain. 2021;37(6):454–74. doi:10.1097/AJP.0000000000000933.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–21. doi:10.1016/j.jpain.2007.09.005.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, Bhagwat D, Everton D, Burke LB, Cowan P, et al. Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain (Amsterdam). 2009;144(1-2):35–42. pain.2009.02.007. doi:10.1016/j.pain.2009.02.007.
   Google Scholar
• Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short‐Form McGill Pain Questionnaire (SF‐MPQ), Chronic Pain Grade Scale (CPGS), Short Form‐36 Bodily Pain Scale (SF‐36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63 Suppl 11(S11):S240–S252. doi:10.1002/acr.20543.
   PubMedGoogle Scholar
• Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7. doi:10.1001/archinte.166.10.1092.
   PubMed Web of Science ®Google Scholar
• Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, Herzberg PY. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008;46(3):266–74. doi:10.1097/MLR.0b013e318160d093.
   PubMed Web of Science ®Google Scholar
• Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24–31. doi:10.1016/j.genhosppsych.2015.11.005.
   PubMed Web of Science ®Google Scholar
• Snyder E, Cai B, DeMuro C, Morrison MF, Ball W. A new single-item Sleep Quality Scale: results of psychometric evaluation in patients with chronic primary insomnia and depression. J Clin Sleep Med. 2018;14(11):1849–57. doi:10.5664/jcsm.7478.
   PubMed Web of Science ®Google Scholar
• Yi H, Shin K, Kim J, Kim J, Lee J, Shin C. Validity and reliability of Sleep Quality Scale in subjects with obstructive sleep apnea syndrome. J Psychosom Res. 2009;66(1):85–8. doi:10.1016/j.jpsychores.2008.07.008.
   PubMed Web of Science ®Google Scholar
• van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15. doi:10.1016/j.jval.2012.02.008.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Position statement on the use of the EQ‐5D‐5L value set for England. [cited 2023 Apr 15]. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l.
   Google Scholar
• Ferguson L, Scheman J. Patient global impression of change scores within the context of a chronic pain rehabilitation program. J Pain. 2009;10(4):S73. doi:10.1016/j.10jpain.2009.01.258.
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009 [cited 2023 Apr 21].
   Google Scholar
• Liu-Seifert H, Zhang S, D’Souza D, Skljarevski V. A closer look at the baseline-observation-carried-forward (BOCF). Patient Prefer Adherence. 2010;4(default):11–6. doi:10.2147/PPA.S8135.
   PubMedGoogle Scholar
• IBM Corp. IBM SPSS Statistics for Macintosh, Version 29.0.2.0. Armonk (NY): IBM Corp; 2023.
   Google Scholar
• GraphPad Prism version 9.5.1 for Macintosh. Boston (MA): GraphPad Software. www.graphpad.com.
   Google Scholar
• Meng H, Page MG, Ajrawat P, Deshpande A, Samman B, Dominicis M, Ladha KS, Fiorellino J, Huang A, Kotteeswaran Y, et al. Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in chronic pain patients. Can J Anaesth. 2021;68(5):633–44. doi:10.1007/s12630-020-01903-1.
   PubMed Web of Science ®Google Scholar
• Vickery AW, Roth S, Ernenwein T, Kennedy J, Washer P. A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years. PLoS One. 2022;17(11):e0272241. doi:10.1371/journal.pone.0272241.
   PubMed Web of Science ®Google Scholar
• Peters L, Peters A, Andreopoulos E, Pollock N, Pande RL, Mochari-Greenberger H. Comparison of DASS-21, PHQ-8, and GAD-7 in a virtual behavioral health care setting. Heliyon. 2021;7(3):e06473. doi:10.1016/j.heliyon.2021.e06473.
   PubMed Web of Science ®Google Scholar
• Moreno-Sanz G, Madiedo A, Lynskey M, Brown MRD. “Flower power”: controlled inhalation of THC-predominant cannabis flos improves health-related quality of life and symptoms of chronic pain and anxiety in eligible UK ­patients. Biomedicines. 2022;10(10):2576. doi:10.3390/biomedicines10102576.
   PubMed Web of Science ®Google Scholar
• Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin J Pain. 2016;32(12):1036–43. doi:10.1097/AJP.0000000000000364.
   PubMed Web of Science ®Google Scholar
• Colizzi M, Bhattacharyya S. Cannabis use and the development of tolerance: a systematic review of human evidence. Neurosci Biobehav Rev. 2018;93:1–25. doi:10.1016/j.neubiorev.2018.07.014.
   PubMed Web of Science ®Google Scholar
• Nasiri N, Nateghi R, Zarei F, Hosseini S, Eslaminejad MB. Mesenchymal stem cell therapy for osteoarthritis: practice and possible promises. In: Advances in experimental medicine and biology. Cham (Switzerland): Springer International Publishing; 2022. p. 107–25.
   Google Scholar
• Heineman JT, Forster GL, Stephens KL, Cottler PS, Timko MP, DeGeorge BR. A randomized controlled trial of topical cannabidiol for the treatment of thumb basal joint arthritis. J Hand Surg Am. 2022;47(7):611–20. jhsa.2022.03.002. doi:10.1016/j.jhsa.2022.03.002.
   PubMed Web of Science ®Google Scholar
• Cahill SP, Lunn SE, Diaz P, Page JE. Evaluation of patient reported safety and efficacy of cannabis from a survey of medical cannabis patients in Canada. Front Public Health. 2021;9:626853. doi:10.3389/fpubh.2021.626853.
   PubMed Web of Science ®Google Scholar
• Ware MA, Wang T, Shapiro S, Collet J, COMPASS Study Team. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain. 2015;16(12):1233–42. doi:10.1016/j.jpain.2015.07.014.
   PubMed Web of Science ®Google Scholar
• Wang T, Collet J, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178(13):1669–78. doi:10.1503/cmaj.071178.
   PubMed Web of Science ®Google Scholar
• Hall W, Solowij N, Lemon J. Theœ health and psychological consequences of cannabis use. Canberra: Australian Government Publ. Service; 1995.
   Google Scholar
• Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJG, Sterne JAC, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336(7644):601–5. doi:10.1136/bmj.39465.451748.AD.
   PubMed Web of Science ®Google Scholar
• Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Benedetti F, Bingel U, Büchel C, Carvalho C, Colagiuri B, et al. Implications of placebo and nocebo effects for clinical practice. Psychother Psychosom. 2018;87(4):204–10. 10. 1159/000490354. doi:10.1159/000490354.
   PubMed Web of Science ®Google Scholar
• Vase L, Petersen GL, Lund K. Placebo effects in idiopathic and neuropathic pain conditions. In: Handbook of experimental pharmacology. Berlin (Germany): Springer Berlin Heidelberg; 2014. p. 121–36.
   Google Scholar
• Gedin F, Blomé S, Pontén M, Lalouni M, Fust J, Raquette A, Vadenmark Lundquist V, Thompson WH, Jensen K. Placebo response and media attention in randomized clinical trials assessing cannabis-based therapies for pain: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(11):e2243848. doi:10.1001/jamanetworkopen.2022.43848.
   PubMed Web of Science ®Google Scholar
• Díaz-Lago M, Blanco F, Matute H. Expensive seems better: the price of a non-effective drug modulates its perceived efficacy. Cogn Res Princ Implic. 2023;8(1):8. doi:10.1186/s41235-023-00463-4.
   PubMed Web of Science ®Google Scholar
• Bar-Lev Schleider L, Mechoulam R, Sikorin I, Naftali T, Novack V. Adherence, safety, and effectiveness of medical cannabis and epidemiological characteristics of the patient population: a prospective study. Front Med (Lausanne). 2022;9:827849. doi:10.3389/fmed.2022.827849.
   PubMed Web of Science ®Google Scholar